Leef Brands (LEEEF) Net Income towards Common Stockholders (2025 - 2026)
Leef Brands (LEEEF) posted Net Income towards Common Stockholders of -$426253.0 for Q1 2026, down 260.38% sequentially from $265776.0 in Q1 2025, and down 260.38% YoY from $265776.0 in Q1 2025.
Leef Brands (LEEEF) Net Income towards Common Stockholders (2025 - 2026) Analysis & Trends
Leef Brands has reported Net Income towards Common Stockholders for 2 years, with the latest figure at -$426253.0 in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 260.38% year-over-year to -$426253.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$160477.0 (changed N/A YoY) and the FY2025 annual result came in at -$17.6 million, up 28.77% from the prior year.
- Net Income towards Common Stockholders fell to -$426253.0 in Q1 2026 per LEEEF's latest filing, from $265776.0 in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $265776.0 in Q1 2025 and troughed at -$426253.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Leef Brands | 59.45 Mn | 54.50 Mn | 2.41 Mn | -1.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.47 Mn |
| Mar 31, 2026 | -426,253.00 |
| Mar 31, 2025 | 265,776.00 |